INTRODUCTION: Previous studies of anti-IL-5/IL-5(R) therapies in severe asthma found that response was mainly predicted by indicators of good baseline disease control. However, long-term response predictors remain unclear. METHODS: Responders to anti-IL-5/IL-5(R) therapy in the well-characterised, real-life, international German Asthma Net (GAN) registry were analysed using regression analyses. Response was defined by
- Bal, C.
- Stoshikj, S.
- Renner, A.
- Milger, K.
- Skowasch, D.
- Schulz, C.
- Jandl, M.
- Schmidt, O.
- Ehmann, R.
- Zehetmayer, S.
- Taube, C.
- Hamelmann, E.
- Buhl, R.
- Korn, S.
- Idzko, M.
Keywords
- Humans
- Female
- *Asthma/drug therapy
- Male
- Middle Aged
- *Interleukin-5/antagonists & inhibitors
- Treatment Outcome
- *Adrenal Cortex Hormones/therapeutic use/administration & dosage
- Adult
- Aged
- *Anti-Asthmatic Agents/therapeutic use/administration & dosage
- Germany/epidemiology
- Registries
- Administration, Inhalation
- Eosinophils
- Antibodies, Monoclonal, Humanized/therapeutic use/administration & dosage
- Disease Progression
- Severity of Illness Index
- Severe asthma
- anti-IL-5/IL-5(R) therapy
- biomarker
- remission
- responder
